Archemix Announces Collaboration with Pfizer to Discover Aptamer Therapeutics

11-Jan-2007

Archemix Corp. announced that it has signed an agreement with Pfizer focused on the discovery of first-in-class aptamers for the development and commercialization as therapeutics. As part of the collaboration, Archemix will use its proprietary SELEX technology to discover and generate product candidates to three disease-associated targets identified by Pfizer. Pfizer will be responsible for developing and commercializing the resulting product candidates.

Under the terms of the agreement, Archemix will receive an upfront cash payment as well as research funding and development milestones. Archemix is also entitled to receive a royalty on any marketed products developed under the collaboration. Detailed financial terms were not disclosed.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance